Neurobiological Tech (NTII) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII)

NTII 0.0001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dr. John M. de Castro who wrote (235)	8/16/1999 2:09:00 PM
From: BRAVEHEART	Read Replies (1) of 1494

Another Article...John this one is directed at you & Terry... See: Message 3286833 Given the prior P-2 trial success of 30% reduction in pain for Nocturnal Diabetic Neuropathies in a mixed trial. What percentage in the current more specific trial would suggest statistical significance and result in advancing to Phase Three testing. Would a similar result give rise to a Phase Three trial? Thanks Jeffrey

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next